InflaRx N.V. (IFRX) is a clinical-stage biopharmaceutical company headquartered in Jena, Germany, that develops inhibitors of the complement factor C5a and its receptor C5aR for inflammatory and autoimmune diseases. Its lead programs are Gohibic (vilobelimab) and the oral candidate izicopan, with a focus on ANCA-associated vasculitis (AAV), inflammatory renal diseases, and hidradenitis suppurativa. As a pre-revenue developer, its stock price is driven almost entirely by clinical progress, financing, and analyst expectations rather than earnings.
The central target reflects eight individually attributable analyst price targets, not a website's headline consensus. The arithmetic mean of these targets is approximately $7.63, rounded to $7.60. The low is Leerink Partners at $2.00 (a December 2025 downgrade to Market Perform), and the high is Guggenheim's Yatin Suneja at $14.00 (May 2026).
Recent actions lean bullish. Raymond James upgraded IFRX to Strong Buy in May 2026 and raised its target from $7 to $9, citing the izicopan AAV program and a $150 million financing that extends runway into proof-of-concept development. H.C. Wainwright's Matthew Keller raised his target to $8 from $6, and Needham initiated coverage with a Buy and an $8 target in September 2026. Cantor Fitzgerald lifted its target to $6 from $4 in August, while Oppenheimer reiterated $9 and LifeSci Capital maintained $5. The wide $2–$14 spread shows analysts are valuing the same pipeline very differently.
IFRX closed at $1.66 on October 27, 2026, up 5.4% on the session, with a market capitalization near $232 million and a 52-week range of $0.80 to $2.95. Moving from $1.66 to $7.60 represents about 358% upside — by any standard a very large move. The stock trades above its 200-day average (near $1.63) but below its 50-day average (near $1.89), reflecting a recent pullback within a longer-term recovery. Reaching $7.60 would almost certainly require positive proof-of-concept clinical data, likely for izicopan in AAV, rather than incremental news flow alone.
Several verified factors could underpin upward movement. The company's pivot toward izicopan in AAV targets validated C5aR biology, with analysts citing potentially improved potency, reduced hepatotoxicity risk, and simpler dosing versus existing therapies. A $150 million financing announced earlier in 2026 extended the cash runway, reducing near-term capital risk. Multiple firms raised targets or upgraded ratings through 2026, signaling improving sentiment, and the pipeline also includes the hidradenitis suppurativa program, which the company has indicated could be partnered.
The risks are substantial and concentrated. As a clinical-stage company, IFRX generates little recurring revenue, so the stock depends on trial outcomes that can fail or be delayed. Future development will likely require additional capital, which could dilute existing holders. Leerink Partners' Market Perform rating with a $2 target underscores a far more conservative view of the same assets. The stock's micro-cap size also leaves it exposed to volatility, and a broad rotation away from speculative biotech or weaker financing conditions could compress valuations regardless of company progress.
The 52-week high near $2.95 is the nearest major overhead resistance, followed by psychological levels that emerge only after a decisive breakout. Support is anchored by the 200-day average near $1.63 and the 52-week low near $0.80. The stock's position between its 50-day and 200-day moving averages indicates the long-term uptrend has not fully reasserted itself, and any move toward $7.60 would first require clearing the prior high with meaningful volume.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may differ. The next earnings release is scheduled for early November 2026. Investors should watch for proof-of-concept data on izicopan in AAV, updates on the hidradenitis suppurativa partnering strategy, additional financing arrangements, and any further analyst revisions. Given the target's distance from the current price, clinical catalysts — not quarterly financials — will be the primary driver.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like IFRX, these signals can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual chart review. Traders looking for a systematic way to track evolving setups can explore the AI Daily Buy/Sell Signals as part of their research process.
Can IFRX reach $7.60? The target is a calculated average of eight analyst price targets spanning $2.00 to $14.00, implying roughly 358% upside from $1.66. Support rests on the izicopan AAV program, a strengthened cash position, and a cluster of bullish revisions in 2026. The obstacles are equally clear: clinical-stage risk, no recurring revenue, likely future dilution, and a wide analyst range that includes a $2 bearish outlier. The wide dispersion means the mean is not a reliable forecast for any individual path. What matters next is clinical data and financing, not the headline target itself.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, IFRX has been loosely correlated with KURA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if IFRX jumps, then KURA could also see price increases.
| Ticker / NAME | Correlation To IFRX | 1D Price Change % | ||
|---|---|---|---|---|
| IFRX | 100% | -2.48% | ||
| KURA - IFRX | 37% Loosely correlated | +2.11% | ||
| VIR - IFRX | 36% Loosely correlated | -0.15% | ||
| SGMT - IFRX | 34% Loosely correlated | +4.78% | ||
| BEAM - IFRX | 34% Loosely correlated | +2.62% | ||
| CRSP - IFRX | 33% Loosely correlated | +1.33% | ||
More | ||||